Phase 3 randomized double-blind trial of pamrevlumab plus systemic corticosteroids in non-ambulatory Duchenne muscular dystrophy

Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Pamrevlumab + systemic corticosteroids with Placebo + systemic corticosteroids (2 arms). Primary endpoints: Primary efficacy endpoints (double-blind phase) and Primary safety endpoints (double-blind phase). Started Aug 2020; status: terminated.